The global Diabetes Drugs market was valued at US$ 97410 million in 2023 and is anticipated to reach US$ 207020 million by 2030, witnessing a CAGR of 11.2% during the forecast period 2024-2030.

Diabetes Drugs Market

Diabetes drugs are treatments for diabetes by lowering the sugar lower in the blood. Diabetes is a kind of disease with common symptoms such as frequent urination, increased thirst and weight loss. The most common drugs used are insulin and oral medications.

Global Diabetes Drugs key players include Novo Nordisk, Sanofi, Eli Lilly, Merck & Co, Boehringer Ingelheim, etc. Global top five manufacturers hold a share over 62%.

In terms of product type, Injection is the largest segment, with a share of 60%. And in terms of application, Hospital has a share about 67 percent.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Diabetes Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diabetes Drugs.

The Diabetes Drugs market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Diabetes Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Diabetes Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Diabetes Drugs Market Report

Report Metric	Details
Report Name	Diabetes Drugs Market
Accounted market size in 2023	US$ 97410 million
Forecasted market size in 2030	US$ 207020 million
CAGR	11.2%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Oral Injection
Segment by Application	Hospital Retail Pharmacy
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Novo Nordisk, Sanofi, Eli Lilly, Merck, AstraZeneca, bayer, Boehringer Ingelheim, Johnson & Johnson, Takeda, Tonghua Dongbao, United Pharmaceuticals, Ganli Pharmaceutical, Biocon, Conker Pharmaceuticals, Jiangsu Wanbang, Geropharm, Wockhardt, Merck Serono, Novartis
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Diabetes Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Diabetes Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Diabetes Drugs Market growing?

Ans: The Diabetes Drugs Market witnessing a CAGR of 11.2% during the forecast period 2024-2030.

What is the Diabetes Drugs Market size in 2030?

Ans: The Diabetes Drugs Market size in 2030 will be US$ 207020 million.

What is the market share of major companies in Diabetes Drugs Market?

Ans: Global top five manufacturers hold a share over 62%.

What is the Diabetes Drugs Market share by type?

Ans: In terms of product type, Injection is the largest segment, with a share of 60%.

Who are the main players in the Diabetes Drugs Market report?

Ans: The main players in the Diabetes Drugs Market are Novo Nordisk, Sanofi, Eli Lilly, Merck, AstraZeneca, bayer, Boehringer Ingelheim, Johnson & Johnson, Takeda, Tonghua Dongbao, United Pharmaceuticals, Ganli Pharmaceutical, Biocon, Conker Pharmaceuticals, Jiangsu Wanbang, Geropharm, Wockhardt, Merck Serono, Novartis

What are the Application segmentation covered in the Diabetes Drugs Market report?

Ans: The Applications covered in the Diabetes Drugs Market report are Hospital, Retail Pharmacy

What are the Type segmentation covered in the Diabetes Drugs Market report?

Ans: The Types covered in the Diabetes Drugs Market report are Oral, Injection

1 Diabetes Drugs Market Overview

1.1 Product Definition

1.2 Diabetes Drugs by Type

1.2.1 Global Diabetes Drugs Market Value Comparison by Type (2024-2030)

1.2.2 Oral

1.2.3 Injection

1.3 Diabetes Drugs by Application

1.3.1 Global Diabetes Drugs Market Value by Application (2024-2030)

1.3.2 Hospital

1.3.3 Retail Pharmacy

1.4 Global Diabetes Drugs Market Size Estimates and Forecasts

1.4.1 Global Diabetes Drugs Revenue 2019-2030

1.4.2 Global Diabetes Drugs Sales 2019-2030

1.4.3 Global Diabetes Drugs Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Diabetes Drugs Market Competition by Manufacturers

2.1 Global Diabetes Drugs Sales Market Share by Manufacturers (2019-2024)

2.2 Global Diabetes Drugs Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Diabetes Drugs Average Price by Manufacturers (2019-2024)

2.4 Global Key Players of Diabetes Drugs, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Diabetes Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Diabetes Drugs, Product Type & Application

2.7 Global Key Manufacturers of Diabetes Drugs, Date of Enter into This Industry

2.8 Global Diabetes Drugs Market Competitive Situation and Trends

2.8.1 Global Diabetes Drugs Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Diabetes Drugs Players Market Share by Revenue

2.8.3 Global Diabetes Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Diabetes Drugs Market Scenario by Region

3.1 Global Diabetes Drugs Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Diabetes Drugs Sales by Region: 2019-2030

3.2.1 Global Diabetes Drugs Sales by Region: 2019-2024

3.2.2 Global Diabetes Drugs Sales by Region: 2025-2030

3.3 Global Diabetes Drugs Revenue by Region: 2019-2030

3.3.1 Global Diabetes Drugs Revenue by Region: 2019-2024

3.3.2 Global Diabetes Drugs Revenue by Region: 2025-2030

3.4 North America Diabetes Drugs Market Facts & Figures by Country

3.4.1 North America Diabetes Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Diabetes Drugs Sales by Country (2019-2030)

3.4.3 North America Diabetes Drugs Revenue by Country (2019-2030)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Diabetes Drugs Market Facts & Figures by Country

3.5.1 Europe Diabetes Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Diabetes Drugs Sales by Country (2019-2030)

3.5.3 Europe Diabetes Drugs Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Diabetes Drugs Market Facts & Figures by Region

3.6.1 Asia Pacific Diabetes Drugs Market Size by Region: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Diabetes Drugs Sales by Region (2019-2030)

3.6.3 Asia Pacific Diabetes Drugs Revenue by Region (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Diabetes Drugs Market Facts & Figures by Country

3.7.1 Latin America Diabetes Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Diabetes Drugs Sales by Country (2019-2030)

3.7.3 Latin America Diabetes Drugs Revenue by Country

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Diabetes Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Diabetes Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Diabetes Drugs Sales by Country (2019-2030)

3.8.3 Middle East and Africa Diabetes Drugs Revenue by Country

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Diabetes Drugs Sales by Type (2019-2030)

4.1.1 Global Diabetes Drugs Sales by Type (2019-2024)

4.1.2 Global Diabetes Drugs Sales by Type (2025-2030)

4.1.3 Global Diabetes Drugs Sales Market Share by Type (2019-2030)

4.2 Global Diabetes Drugs Revenue by Type (2019-2030)

4.2.1 Global Diabetes Drugs Revenue by Type (2019-2024)

4.2.2 Global Diabetes Drugs Revenue by Type (2025-2030)

4.2.3 Global Diabetes Drugs Revenue Market Share by Type (2019-2030)

4.3 Global Diabetes Drugs Price by Type (2019-2030)

5 Segment by Application

5.1 Global Diabetes Drugs Sales by Application (2019-2030)

5.1.1 Global Diabetes Drugs Sales by Application (2019-2024)

5.1.2 Global Diabetes Drugs Sales by Application (2025-2030)

5.1.3 Global Diabetes Drugs Sales Market Share by Application (2019-2030)

5.2 Global Diabetes Drugs Revenue by Application (2019-2030)

5.2.1 Global Diabetes Drugs Revenue by Application (2019-2024)

5.2.2 Global Diabetes Drugs Revenue by Application (2025-2030)

5.2.3 Global Diabetes Drugs Revenue Market Share by Application (2019-2030)

5.3 Global Diabetes Drugs Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Novo Nordisk

6.1.1 Novo Nordisk Company Information

6.1.2 Novo Nordisk Description and Business Overview

6.1.3 Novo Nordisk Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Novo Nordisk Diabetes Drugs Product Portfolio

6.1.5 Novo Nordisk Recent Developments/Updates

6.2 Sanofi

6.2.1 Sanofi Company Information

6.2.2 Sanofi Description and Business Overview

6.2.3 Sanofi Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Sanofi Diabetes Drugs Product Portfolio

6.2.5 Sanofi Recent Developments/Updates

6.3 Eli Lilly

6.3.1 Eli Lilly Company Information

6.3.2 Eli Lilly Description and Business Overview

6.3.3 Eli Lilly Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Eli Lilly Diabetes Drugs Product Portfolio

6.3.5 Eli Lilly Recent Developments/Updates

6.4 Merck

6.4.1 Merck Company Information

6.4.2 Merck Description and Business Overview

6.4.3 Merck Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Merck Diabetes Drugs Product Portfolio

6.4.5 Merck Recent Developments/Updates

6.5 AstraZeneca

6.5.1 AstraZeneca Company Information

6.5.2 AstraZeneca Description and Business Overview

6.5.3 AstraZeneca Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.5.4 AstraZeneca Diabetes Drugs Product Portfolio

6.5.5 AstraZeneca Recent Developments/Updates

6.6 bayer

6.6.1 bayer Company Information

6.6.2 bayer Description and Business Overview

6.6.3 bayer Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.6.4 bayer Diabetes Drugs Product Portfolio

6.6.5 bayer Recent Developments/Updates

6.7 Boehringer Ingelheim

6.7.1 Boehringer Ingelheim Company Information

6.7.2 Boehringer Ingelheim Description and Business Overview

6.7.3 Boehringer Ingelheim Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.7.4 Boehringer Ingelheim Diabetes Drugs Product Portfolio

6.7.5 Boehringer Ingelheim Recent Developments/Updates

6.8 Johnson & Johnson

6.8.1 Johnson & Johnson Company Information

6.8.2 Johnson & Johnson Description and Business Overview

6.8.3 Johnson & Johnson Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Johnson & Johnson Diabetes Drugs Product Portfolio

6.8.5 Johnson & Johnson Recent Developments/Updates

6.9 Takeda

6.9.1 Takeda Company Information

6.9.2 Takeda Description and Business Overview

6.9.3 Takeda Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Takeda Diabetes Drugs Product Portfolio

6.9.5 Takeda Recent Developments/Updates

6.10 Tonghua Dongbao

6.10.1 Tonghua Dongbao Company Information

6.10.2 Tonghua Dongbao Description and Business Overview

6.10.3 Tonghua Dongbao Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Tonghua Dongbao Diabetes Drugs Product Portfolio

6.10.5 Tonghua Dongbao Recent Developments/Updates

6.11 United Pharmaceuticals

6.11.1 United Pharmaceuticals Company Information

6.11.2 United Pharmaceuticals Description and Business Overview

6.11.3 United Pharmaceuticals Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.11.4 United Pharmaceuticals Diabetes Drugs Product Portfolio

6.11.5 United Pharmaceuticals Recent Developments/Updates

6.12 Ganli Pharmaceutical

6.12.1 Ganli Pharmaceutical Company Information

6.12.2 Ganli Pharmaceutical Description and Business Overview

6.12.3 Ganli Pharmaceutical Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Ganli Pharmaceutical Diabetes Drugs Product Portfolio

6.12.5 Ganli Pharmaceutical Recent Developments/Updates

6.13 Biocon

6.13.1 Biocon Company Information

6.13.2 Biocon Description and Business Overview

6.13.3 Biocon Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.13.4 Biocon Diabetes Drugs Product Portfolio

6.13.5 Biocon Recent Developments/Updates

6.14 Conker Pharmaceuticals

6.14.1 Conker Pharmaceuticals Company Information

6.14.2 Conker Pharmaceuticals Description and Business Overview

6.14.3 Conker Pharmaceuticals Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.14.4 Conker Pharmaceuticals Diabetes Drugs Product Portfolio

6.14.5 Conker Pharmaceuticals Recent Developments/Updates

6.15 Jiangsu Wanbang

6.15.1 Jiangsu Wanbang Company Information

6.15.2 Jiangsu Wanbang Description and Business Overview

6.15.3 Jiangsu Wanbang Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.15.4 Jiangsu Wanbang Diabetes Drugs Product Portfolio

6.15.5 Jiangsu Wanbang Recent Developments/Updates

6.16 Geropharm

6.16.1 Geropharm Company Information

6.16.2 Geropharm Description and Business Overview

6.16.3 Geropharm Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.16.4 Geropharm Diabetes Drugs Product Portfolio

6.16.5 Geropharm Recent Developments/Updates

6.17 Wockhardt

6.17.1 Wockhardt Company Information

6.17.2 Wockhardt Description and Business Overview

6.17.3 Wockhardt Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.17.4 Wockhardt Diabetes Drugs Product Portfolio

6.17.5 Wockhardt Recent Developments/Updates

6.18 Merck Serono

6.18.1 Merck Serono Company Information

6.18.2 Merck Serono Description and Business Overview

6.18.3 Merck Serono Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.18.4 Merck Serono Diabetes Drugs Product Portfolio

6.18.5 Merck Serono Recent Developments/Updates

6.19 Novartis

6.19.1 Novartis Company Information

6.19.2 Novartis Description and Business Overview

6.19.3 Novartis Diabetes Drugs Sales, Revenue and Gross Margin (2019-2024)

6.19.4 Novartis Diabetes Drugs Product Portfolio

6.19.5 Novartis Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Diabetes Drugs Industry Chain Analysis

7.2 Diabetes Drugs Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Diabetes Drugs Production Mode & Process

7.4 Diabetes Drugs Sales and Marketing

7.4.1 Diabetes Drugs Sales Channels

7.4.2 Diabetes Drugs Distributors

7.5 Diabetes Drugs Customers

8 Diabetes Drugs Market Dynamics

8.1 Diabetes Drugs Industry Trends

8.2 Diabetes Drugs Market Drivers

8.3 Diabetes Drugs Market Challenges

8.4 Diabetes Drugs Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Astrazeneca plc

Bayer

Biocon Ltd.

Boehringer Ingelheim

Merck

Novartis

Takeda

Tonghua Dongbao

United Pharmaceuticals

Conker Pharmaceuticals

List of Tables

Table 1. Global Diabetes Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Diabetes Drugs Market Value by Application (2024-2030) & (US$ Million)

Table 3. Global Diabetes Drugs Market Competitive Situation by Manufacturers in 2023

Table 4. Global Diabetes Drugs Sales (M Units) of Key Manufacturers (2019-2024)

Table 5. Global Diabetes Drugs Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Diabetes Drugs Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Diabetes Drugs Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Diabetes Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Diabetes Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Diabetes Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Diabetes Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Diabetes Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Diabetes Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Diabetes Drugs as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Diabetes Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Diabetes Drugs Sales by Region (2019-2024) & (M Units)

Table 18. Global Diabetes Drugs Sales Market Share by Region (2019-2024)

Table 19. Global Diabetes Drugs Sales by Region (2025-2030) & (M Units)

Table 20. Global Diabetes Drugs Sales Market Share by Region (2025-2030)

Table 21. Global Diabetes Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Diabetes Drugs Revenue Market Share by Region (2019-2024)

Table 23. Global Diabetes Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Diabetes Drugs Revenue Market Share by Region (2025-2030)

Table 25. North America Diabetes Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Diabetes Drugs Sales by Country (2019-2024) & (M Units)

Table 27. North America Diabetes Drugs Sales by Country (2025-2030) & (M Units)

Table 28. North America Diabetes Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Diabetes Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Diabetes Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Diabetes Drugs Sales by Country (2019-2024) & (M Units)

Table 32. Europe Diabetes Drugs Sales by Country (2025-2030) & (M Units)

Table 33. Europe Diabetes Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Diabetes Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Diabetes Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Diabetes Drugs Sales by Region (2019-2024) & (M Units)

Table 37. Asia Pacific Diabetes Drugs Sales by Region (2025-2030) & (M Units)

Table 38. Asia Pacific Diabetes Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Diabetes Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Diabetes Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Diabetes Drugs Sales by Country (2019-2024) & (M Units)

Table 42. Latin America Diabetes Drugs Sales by Country (2025-2030) & (M Units)

Table 43. Latin America Diabetes Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Diabetes Drugs Revenue Market Share by Country (2019-2024)

Table 45. Middle East and Africa Diabetes Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East and Africa Diabetes Drugs Sales by Country (2019-2024) & (M Units)

Table 47. Middle East and Africa Diabetes Drugs Sales by Country (2025-2030) & (M Units)

Table 48. Middle East and Africa Diabetes Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East and Africa Diabetes Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Diabetes Drugs Sales (M Units) by Type (2019-2024)

Table 51. Global Diabetes Drugs Sales (M Units) by Type (2025-2030)

Table 52. Global Diabetes Drugs Sales Market Share by Type (2019-2024)

Table 53. Global Diabetes Drugs Sales Market Share by Type (2025-2030)

Table 54. Global Diabetes Drugs Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Diabetes Drugs Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Diabetes Drugs Revenue Market Share by Type (2019-2024)

Table 57. Global Diabetes Drugs Revenue Market Share by Type (2025-2030)

Table 58. Global Diabetes Drugs Price (US$/Unit) by Type (2019-2024)

Table 59. Global Diabetes Drugs Price (US$/Unit) by Type (2025-2030)

Table 60. Global Diabetes Drugs Sales (M Units) by Application (2019-2024)

Table 61. Global Diabetes Drugs Sales (M Units) by Application (2025-2030)

Table 62. Global Diabetes Drugs Sales Market Share by Application (2019-2024)

Table 63. Global Diabetes Drugs Sales Market Share by Application (2025-2030)

Table 64. Global Diabetes Drugs Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Diabetes Drugs Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Diabetes Drugs Revenue Market Share by Application (2019-2024)

Table 67. Global Diabetes Drugs Revenue Market Share by Application (2025-2030)

Table 68. Global Diabetes Drugs Price (US$/Unit) by Application (2019-2024)

Table 69. Global Diabetes Drugs Price (US$/Unit) by Application (2025-2030)

Table 70. Novo Nordisk Company Information

Table 71. Novo Nordisk Description and Business Overview

Table 72. Novo Nordisk Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Novo Nordisk Diabetes Drugs Product

Table 74. Novo Nordisk Recent Developments/Updates

Table 75. Sanofi Company Information

Table 76. Sanofi Description and Business Overview

Table 77. Sanofi Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. Sanofi Diabetes Drugs Product

Table 79. Sanofi Recent Developments/Updates

Table 80. Eli Lilly Company Information

Table 81. Eli Lilly Description and Business Overview

Table 82. Eli Lilly Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Eli Lilly Diabetes Drugs Product

Table 84. Eli Lilly Recent Developments/Updates

Table 85. Merck Company Information

Table 86. Merck Description and Business Overview

Table 87. Merck Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Merck Diabetes Drugs Product

Table 89. Merck Recent Developments/Updates

Table 90. AstraZeneca Company Information

Table 91. AstraZeneca Description and Business Overview

Table 92. AstraZeneca Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. AstraZeneca Diabetes Drugs Product

Table 94. AstraZeneca Recent Developments/Updates

Table 95. bayer Company Information

Table 96. bayer Description and Business Overview

Table 97. bayer Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. bayer Diabetes Drugs Product

Table 99. bayer Recent Developments/Updates

Table 100. Boehringer Ingelheim Company Information

Table 101. Boehringer Ingelheim Description and Business Overview

Table 102. Boehringer Ingelheim Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Boehringer Ingelheim Diabetes Drugs Product

Table 104. Boehringer Ingelheim Recent Developments/Updates

Table 105. Johnson & Johnson Company Information

Table 106. Johnson & Johnson Description and Business Overview

Table 107. Johnson & Johnson Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Johnson & Johnson Diabetes Drugs Product

Table 109. Johnson & Johnson Recent Developments/Updates

Table 110. Takeda Company Information

Table 111. Takeda Description and Business Overview

Table 112. Takeda Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Takeda Diabetes Drugs Product

Table 114. Takeda Recent Developments/Updates

Table 115. Tonghua Dongbao Company Information

Table 116. Tonghua Dongbao Description and Business Overview

Table 117. Tonghua Dongbao Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Tonghua Dongbao Diabetes Drugs Product

Table 119. Tonghua Dongbao Recent Developments/Updates

Table 120. United Pharmaceuticals Company Information

Table 121. United Pharmaceuticals Description and Business Overview

Table 122. United Pharmaceuticals Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. United Pharmaceuticals Diabetes Drugs Product

Table 124. United Pharmaceuticals Recent Developments/Updates

Table 125. Ganli Pharmaceutical Company Information

Table 126. Ganli Pharmaceutical Description and Business Overview

Table 127. Ganli Pharmaceutical Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 128. Ganli Pharmaceutical Diabetes Drugs Product

Table 129. Ganli Pharmaceutical Recent Developments/Updates

Table 130. Biocon Company Information

Table 131. Biocon Description and Business Overview

Table 132. Biocon Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 133. Biocon Diabetes Drugs Product

Table 134. Biocon Recent Developments/Updates

Table 135. Conker Pharmaceuticals Company Information

Table 136. Conker Pharmaceuticals Description and Business Overview

Table 137. Conker Pharmaceuticals Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 138. Conker Pharmaceuticals Diabetes Drugs Product

Table 139. Conker Pharmaceuticals Recent Developments/Updates

Table 140. Jiangsu Wanbang Company Information

Table 141. Jiangsu Wanbang Description and Business Overview

Table 142. Jiangsu Wanbang Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 143. Jiangsu Wanbang Diabetes Drugs Product

Table 144. Jiangsu Wanbang Recent Developments/Updates

Table 145. Geropharm Company Information

Table 146. Geropharm Description and Business Overview

Table 147. Geropharm Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 148. Geropharm Diabetes Drugs Product

Table 149. Geropharm Recent Developments/Updates

Table 150. Wockhardt Company Information

Table 151. Wockhardt Description and Business Overview

Table 152. Wockhardt Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 153. Wockhardt Diabetes Drugs Product

Table 154. Wockhardt Recent Developments/Updates

Table 155. Merck Serono Company Information

Table 156. Merck Serono Description and Business Overview

Table 157. Merck Serono Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 158. Merck Serono Diabetes Drugs Product

Table 159. Merck Serono Recent Developments/Updates

Table 160. Novartis Company Information

Table 161. Novartis Description and Business Overview

Table 162. Novartis Diabetes Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 163. Novartis Diabetes Drugs Product

Table 164. Novartis Recent Developments/Updates

Table 165. Key Raw Materials Lists

Table 166. Raw Materials Key Suppliers Lists

Table 167. Diabetes Drugs Distributors List

Table 168. Diabetes Drugs Customers List

Table 169. Diabetes Drugs Market Trends

Table 170. Diabetes Drugs Market Drivers

Table 171. Diabetes Drugs Market Challenges

Table 172. Diabetes Drugs Market Restraints

Table 173. Research Programs/Design for This Report

Table 174. Key Data Information from Secondary Sources

Table 175. Key Data Information from Primary Sources

Table 176. Authors List of This Report

List of Figures

Figure 1. Product Picture of Diabetes Drugs

Figure 2. Global Diabetes Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Diabetes Drugs Market Share by Type: 2023 & 2030

Figure 4. Oral Product Picture

Figure 5. Injection Product Picture

Figure 6. Global Diabetes Drugs Market Value by Application (2024-2030) & (US$ Million)

Figure 7. Global Diabetes Drugs Market Share by Application: 2023 & 2030

Figure 8. Hospital

Figure 9. Retail Pharmacy

Figure 10. Global Diabetes Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 11. Global Diabetes Drugs Market Size (2019-2030) & (US$ Million)

Figure 12. Global Diabetes Drugs Sales (2019-2030) & (M Units)

Figure 13. Global Diabetes Drugs Average Price (US$/Unit) & (2019-2030)

Figure 14. Diabetes Drugs Report Years Considered

Figure 15. Diabetes Drugs Sales Share by Manufacturers in 2023

Figure 16. Global Diabetes Drugs Revenue Share by Manufacturers in 2023

Figure 17. Global 5 and 10 Largest Diabetes Drugs Players: Market Share by Revenue in Diabetes Drugs in 2023

Figure 18. Diabetes Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 19. Global Diabetes Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 20. North America Diabetes Drugs Sales Market Share by Country (2019-2030)

Figure 21. North America Diabetes Drugs Revenue Market Share by Country (2019-2030)

Figure 22. U.S. Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 23. Canada Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 24. Europe Diabetes Drugs Sales Market Share by Country (2019-2030)

Figure 25. Europe Diabetes Drugs Revenue Market Share by Country (2019-2030)

Figure 26. Germany Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. France Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. U.K. Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. Italy Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. Russia Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Asia Pacific Diabetes Drugs Sales Market Share by Region (2019-2030)

Figure 32. Asia Pacific Diabetes Drugs Revenue Market Share by Region (2019-2030)

Figure 33. China Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Japan Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. South Korea Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. India Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Australia Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. China Taiwan Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Indonesia Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Thailand Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Malaysia Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Latin America Diabetes Drugs Sales Market Share by Country (2019-2030)

Figure 43. Mexico Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Brazil Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Argentina Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Middle East and Africa Diabetes Drugs Sales Market Share by Country (2019-2030)

Figure 47. Middle East and Africa Diabetes Drugs Revenue Market Share by Country (2019-2030)

Figure 48. Turkey Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Saudi Arabia Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. UAE Diabetes Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Global Sales Market Share of Diabetes Drugs by Type (2019-2030)

Figure 52. Global Revenue Market Share of Diabetes Drugs by Type (2019-2030)

Figure 53. Global Diabetes Drugs Price (US$/Unit) by Type (2019-2030)

Figure 54. Global Sales Market Share of Diabetes Drugs by Application (2019-2030)

Figure 55. Global Revenue Market Share of Diabetes Drugs by Application (2019-2030)

Figure 56. Global Diabetes Drugs Price (US$/Unit) by Application (2019-2030)

Figure 57. Diabetes Drugs Value Chain

Figure 58. Diabetes Drugs Production Process

Figure 59. Channels of Distribution (Direct Vs Distribution)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions